fbpx
    • Myeloma Crowd Newsroom
    • Uncategorized
    • Mar 05, 2014

    Cure Panel Features Jenny Ahlstrom’s Journey of Myeloma Survivorship

jenny-bio-100x100Myeloma Crowd founder, Jenny Ahlstrom, is featured in Cure Panel’s newsletter. Read about her journey here.

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

MYELOMA CROWD RESEARCH INITIATIVE
$162519 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile
More Articles
disparities

ASCO Life With Multiple Myeloma

Addressing Disparities in Myeloma Care

Jul 03, 2019

By Cindy Chmielewski @MyelomaTeacher I arrived for the first time at the Chicago ASCO annual meeting with the theme Caring for Every Patient, Learning from Every Patient. I received a Conquer Cancer scholarship to attend this conference. My ASCO experience started by attending an education session entitled Many Shades of Disparities in Myeloma Care. The […]

Multiple Myeloma News

FDA Accepts Application for New Engineered Toxin Body Drug by Takeda Oncology and Molecular Templates

Jul 13, 2019

Molecular Templates and Takeda Oncology are teaming up to develop a new class of targeted biologic therapeutics for myeloma patients. The FDA has now accepted the application for TAK-169, an Engineered Toxin Body (EBT) targeting CD38. Together, they plan to conduce a Phase I trial for relapsed/refractory myeloma patients.  According to Eric Pooma, PhD, CEO […]

Myeloma Clinical Trials

Clinical Trial: Daratumumab, Ixazomib, and Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)

May 23, 2019

A phase II study is open evaluating how well daratumumab, ixazomib, and dexamethasone work with or without bortezomib in treating patients with newly diagnosed multiple myeloma. Please not that for one of the patient groups, it will use two different types of proteasome inhibitors in consecutive order.  Open-Label: Patients and their doctors will know both the […]

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: